Acquired Malignant Nonmalignant Congenital Acute nonlymphoblastic Leukemia Acute lymphoblastic leukemia Chronic myelogenous leukemia Chronic lymphocytic leukemia Non-Hodgkin lymphoma Hodgkin disease Multiple myeloma Myelodysplastic Syndrome Myelofibrosis Agnogenic myeloid metaplasia P. vera…
Herpesviruses Herpes simplex type 1 Herpes simplex type 2 Cytomegalovirus Varicella zoster virus Epstein–Barr virus Human herpesvirus 6 Intestinal viruses Rotavirus Norwalk virus Adenoviruses Astroviruses Coxsackie Caliciviruses Respiratory viruses Respiratory…
Non-hyperdiploid MM Hyperdiploid MM Translocations Less translocations Younger Older IgA IgG Lambda Kappa Less bone disease More bone disease More aggressive More indolent Females Males Chromosome 13 deleted Chromosome 13…
Classification Stage I Involvement of a single lymph node region or lymphoid structure (e.g., spleen, thymus, Waldeyer’s ring) or involvement of a single extralymphatic site (IE) Stage II Involvement of…
Fig. 25.1 The incidence of MDS and age. Age adjusted incidence/100,000 individuals. Age in five block years. (Data from Rollison DE, Howlader N, Smith MT et al. Epidemiology of myelodysplastic…
B lymphoblastic leukemia B lymphoblastic leukemia, not otherwise specified B lymphoblastic leukemia with recurrent genetic abnormalities B lymphoblastic leukemia with t(9;22)(q34;q11.2); BCR-ABL1 B lymphoblastic leukemia with t(v;11q23); MLL rearranged B…
3. Murphy S, Gardner FH. Room temperature storage of platelets. Transfusion. 1976;16:2–3.PubMedCrossRef 4. Hogge DE, Thompson BW, Schiffer CA. Platelet storage for 7 days in second-generation blood bags. Transfusion. 1986;26:131–5.PubMedCrossRef…
Risk factor for infection Risk category Low High General condition including organ function Performance status Good Poor Renal failure No Yes Liver failure No Yes Lung disease No Yes Diabetes…
•Incidence: 1 % •Associated features –Plasmablastic morphology –Other extramedullary locations –Plasma cell leukemia –Increased lactate dehydrogenase •MRI: diffuse leptomeningeal enhancement (with or without masses) •Median survival: 3 months Modified with…
Alkylating agent therapy DNA-topoisomerase II inhibitor therapy (epipodophyllotoxins and anthracyclines) Intense therapy High doses of chemotherapy for prolonged periods as in therapy for Hodgkin’s disease and non-Hodgkin’s lymphoma Direct correlation…
